Poloxamer 407

To evaluate the Antihyperlipedimic activity of ethanol root extract of Carica papaya in wistar rat .The pulverized plant materials were taken up for extraction using hydro alcohol in the proportion of 5:95. The extraction was carried out by continuous cold percolation method Antihyperlipedimic activity was carried out using poloxamer 407 induced hyperlipidemia in wistar rat at the dose level of 100 mg/kg p.o and 200 mg/kg p.o. Oral administration of ethanol   root extract of carica papaya (ERCP) significantly reduced the level of  TC, TG, LDL and VLDL, while increasing (p< 0.001) HDL – C levels compared to control and standard drug Atorvastatin 10mg/kg.. Significant lowering of TC and an increase in HDL are very desirable biochemical state for the prevention of atherosclerosis and ischemic condition. The results of this study suggested that (ERCP) possessed potent anti-hyperlipidemic activity in poloxamer-407 induced hyperlipidemia in Wistar rats, as was evident from the reduced levels of TC, TG, LDL and VLDL.

The present study involved preparation of solid dispersions of Olmesartan medoxomil to improve the aqueous solubility and dissolution rate in order to enhance bioavailability. Olmesartan is a BCS Class II anti-hypertensive drug, having low aqueous solubility and low bioavailability of 26%.  In the present study, solid dispersions of Olmesartan with different carriers like Poloxamer 407, PEG 4000  and crospovidone in different ratios (1 : 1, 1 : 2, 1 : 3, 1 : 4) were prepared by solvent evaporation method.  The formulations were further characterized for percentage yield, drug content, in vitro release study,  and stability study. In vitro release studies revealed that the solid dispersions prepared by solvent evaporation method crospovidone (1 : 4) was considered as the best formulation because of its faster drug release among all formulations.  Infrared spectroscopy (IR) studies revealed that no interactions exist between drug and polymer. Powder X-ray diffraction studies showed a significant decrease in crystalline nature of drug in solid dispersions. In conclusion, solid dispersions of Olmesartan in crospovidone (1:4) have shown to be a promising approach to enhance the bioavailability of Olmesartan.

In the present work Tadalafil fast disintegrating tablets were prepared with poloxamer as carrier to enhance the solubility of Tadalafil and in order to disperse at faster rate in the mouth. Chemically Tadalafil is (6R,12aR)-6-(1,3-Benzodioxol-yl) 2,3,6,7,12,12a hexahydro-2-methylpyrazino[10,20:1,6] pyrido [3,4-b]indole-1,4-dione used in erectile dysfunction. In this current work Tadalafil fast disintegrating tablets were formulated from F1-F12 by direct compression method by taking 1:1, 1:2 and 1:3 ratio of poloxamer as a water soluble polymer and super disintegrating agents such as crospovidine, croscarmellose sodium, sodium starch glycolate and kryon. There after FT-IR studies were performed and it was observed that there were no incompatible reactions found between the Tadalafil and excipients used in formulations. Then all the formulations of Tadalafil fast disintegrating tablets F1-F12 were evaluated for pre and post compressional parameters including in-vitro dissolution studies. In which formulation F-12, containing (1:3) ratio of drug-poloxamer and kryon as super disintegrating agent was shown significant changes in wetting time (13±2.09sec), dispersion time (36±3.605sec) and fastest percentage drug release of 99.27±2.78 within 30 minutes was observed.

The field of Ocular drug delivery is one of the interesting and challenging endeavors facing the pharmaceutical scientist. The most frequently used dosage forms i.e. ophthalmic solutions and suspensions are compromised in their effectiveness by several limitations, leading poor ocular bioavailability. In situ hydrogels are instilled as drops into the eye and undergoes a sol to gel transition in the cul-de-sac, improved ocular bioavailability by increasing the duration of contact with corneal tissue, thereby reducing the frequency of administration. The purpose of the present work was to develop an ophthalmic in situ gel of Moxifloxacin HCl a fluoroquinolone antibiotic. Poloxamer 407 a temperature sensitive gelling agent was employed for the formation of in situ hydrogel along with sodium alginate as a mucoadhesive polymer. In-situ gel was evaluated for various parameters like appearance, pH, drug content, gelling capacity, gel strength, bioadhesion, viscosity, In-vitro drug release, isotonicity, sterility, antifungal activity, ocular irritancy and stability studies. The gel strength, bioadhesion and isotonicity shown quality parameter for ophthalmic formulation. The optimized formulation containing 10% w/v poloxamer 407 and 0.1% w/v sodium alginate have shown 96.84% drug release up to 8 hrs. This is sufficient for antibacterial activity. Drug release kinetic study shown that a Korsmeyers-peppas is the best-fit model. This study found that an optimized formulation having improved viscosity and better mucoadhesive property may improve the bioavaibility of ocular administration of moxifloxacin HCl in in-situ gel form and can be alternative to the conventionally administered oral formulation and effectively used to prolong residence time.